查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球神經內分泌腫瘤治療市場 - 2023-2030
市場調查報告書
商品編碼
1279680

全球神經內分泌腫瘤治療市場 - 2023-2030

Global Neuroendocrine Tumor Treatment Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

全球神經內分泌腫瘤治療市場預計將出現有利可圖的增長，到 2022 年將達到 50.532 億美元，到 2030 年將達到 103.987 億美元。 神經內分泌腫瘤治療市場預計在預測期內（2023-2030 年）的複合年增長率為 9.7%。 主要市場參與者正在尋求各種戰略，包括併購、產品批准和協議，以擴大產品範圍和加強產品組合，以進入神經內分泌腫瘤治療市場，擴大業務範圍，提高競爭力。

例如，2022 年 9 月 21 日，禮來公司宣布，美國食品和藥物管理局 (FDA) 確定 RET（在宣布批准 Rethmo（Selpercatinum，40 毫克和 80 毫克膠囊）期間重新排列）用於成人患者局部晚期或轉移性實體瘤轉染）基因融合。 該適應症根據 ORR 和反應持續時間 (DOR) 獲得加速批准。 對該適應症的持續批准可能取決於驗證性研究中臨床效用的驗證和描述。

神經內分泌腫瘤病例數量的增加、產品批准的增加、研究的增加以及意識的提高是推動全球神經內分泌腫瘤治療市場增長的因素。

市場動態

越來越多的臨床研究正在推動全球神經內分泌腫瘤治療市場的增長。

越來越多的旨在治療神經內分泌腫瘤的臨床研究正在推動全球神經內分泌腫瘤治療市場的增長。 例如，2022 年 9 月，美國國家癌症研究所宣佈在 NIH 臨床中心進行一項新的 I/II 期臨床試驗，以針對無法手術或轉移性神經內分泌腫瘤。兩種被認為以相似方式起作用的藥物的混合物的療效被評估。 一種藥物 lutathera 會照射身體以誘導 DNA 損傷，而第二種藥物 PARP 抑製劑奧拉帕尼會阻止 DNA 損傷的修復。

政府的努力和增加的資金為全球神經內分泌腫瘤治療市場提供了增長機會

不斷增加的政府資金和舉措為未來幾年全球神經內分泌腫瘤治療市場帶來了充滿希望的增長機會。 例如，2022 年 1 月，澳大利亞聯邦衛生部針對 2021 年罕見癌症、罕見疾病和未滿足需求 (RCRDUN) 的資金展望，宣布了 6340 萬美元用於研究罕見疾病和罕見癌症的資金，並提供了美元贈款。

COVID-19 影響分析

COVID-19 分析包括 COVID 之前、COVID 和 COVID 之後的情景、價格動態（與 COVID 之前的情景相比，大流行期間和之後的價格變化）、供需範圍（貿易導致的需求和供應變化）限制、封鎖和後續問題）；我打算解釋製造商為此做了什麼。

俄烏衝突分析

2022年2月24日，俄羅斯聯邦入侵烏克蘭，在居民中造成極大混亂，1200萬人背井離鄉尋求庇護。 超過 700 萬人逃往烏克蘭的其他地區，500 萬人逃往邊境國家。 這阻礙了該地區的市場增長，並對全球市場增長產生負面影響。

全球經濟衰退影響分析

醫療保健行業並非完全不受經濟衰退的影響，即使在過去的金融危機期間，醫療機構也在考慮裁員和招聘。 但由於其固有的性質，它比其他部門處理得更好。 然而，隨著通脹繼續上升，經濟衰退危機威脅著市場。 經濟衰退將繼續的緊張局勢正在加劇。

人工智能影響分析

在癌症診斷、藥物發現和腫瘤精準醫學中採用人工智能和機器學習來提高治療標準和患者體驗，將在預測期內推動全球神經內分泌腫瘤治療市場產生積極影響

內容

第一章調查方法及範圍

  • 調查方法
  • 調查目的和範圍

第 2 章定義和概述

第 3 章執行摘要

  • 按處理分類的片段
  • 按指示摘錄
  • 按給藥途徑分類的片段
  • 最終用戶

第四章市場動態

  • 影響因素
    • 司機
      • 神經內分泌腫瘤病例數增加
      • 產品批准
      • 啟動研究活動
    • 約束因素
      • 治療的副作用
    • 機會
    • 政府舉措
    • 影響分析

第五章行業分析

  • 波特的五力分析
  • 監管分析
  • 價格分析
  • 專利分析
  • 害蟲分析
  • 管道分析

第 6 章 COVID-19 分析

  • COVID-19 分析
    • COVID-19 之前的情景
    • 當前的 COVID-19 情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格和動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 結論

第七章俄烏衝突分析

第八章全球經濟衰退分析

第9章人工智能的影響分析

第 10 章按藥物類型分類

  • 生長抑素類似物 (SSA)
  • 靶向藥物
  • 其他

第11章適應症

  • 消化系統
  • 肺
  • 胰腺
  • 其他

第12章給藥途徑

  • 口語
  • 注射

第 13 章最終用戶

  • 醫院
  • 癌症研究中心
  • 門診手術中心

第14章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第15章競爭格局

  • 競爭場景
  • 市場份額分析
  • 併購分析

第十六章公司簡介

  • 輝瑞公司
    • 公司簡介
    • 治療類型組合和說明
    • 財務摘要
    • 主要發展狀況
  • Ipsen Pharmaceuticals
  • Novartis
  • AVEO Pharmaceuticals, Inc.
  • Eli Lilly & Company
  • CK Hutchison Holdings（HUTCHMED）
  • C.H. Boehringer Sohn Ag & Co. KG（Boehringer Ingelheim International GmbH）
  • Lantheus Holdings, Inc.
  • Merck & Co., Inc.
  • Sanofi

第17章 附錄

簡介目錄
Product Code: PH2122

Market Overview

The global neuroendocrine tumor treatment market reached USD 5,053.2 million in 2022 and is projected to witness lucrative growth by reaching up to USD 10,398.7 million by 2030. The neuroendocrine tumor treatment market is expected to exhibit a CAGR of 9.7% during the forecast period (2023-2030). The key market players are adopting various strategies such as mergers and acquisitions, product approvals, and agreements to increase product reach and strengthen their product portfolios, in order to enter or expand their business offerings and competitiveness in the neuroendocrine tumor treatment market.

For instance, on September 21, 2022, Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) approved Retevmo (selpercatinib, 40 mg & 80 mg capsules) for adult patients with locally advanced or metastatic solid tumors with a rearranged during transfection (RET) gene fusion that has progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on ORR and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial.

The growing cases of neuroendocrine tumors, increasing product approvals, growing research, and increasing awareness are the factors driving global neuroendocrine tumor treatment market growth.

Market Dynamics

The Increasing Number of Clinical Research is Driving the Global Neuroendocrine Tumor Treatment Market Growth.

The growing number of clinical research for the treatment of neuroendocrine tumors is driving the global neuroendocrine tumor treatment market growth. For instance, according to a new published by National Cancer Institute in September 2022, a phase I/II clinical trial at the NIH Clinical Center assesses the efficacy of a mixture of two medications that may function in complementary manners to target inoperable or metastatic neuroendocrine tumors. One agent, lutathera, radiates radiation inside the body, inducing DNA damage, and the second agent, olaparib, a PARP inhibitor, stops the restoration of DNA breaks.

The Increasing Government Initiatives and Funding Provide Growth Opportunities to the Global Neuroendocrine Tumor Treatment Market

The increasing government funding and initiatives are presenting the global neuroendocrine tumor treatment market with prospective growth opportunities in the upcoming years. For instance, in January 2022, the Department of Health of the Commonwealth of Australia provided a grant of USD 63.4 million for the rare diseases and rare cancers investigation in response to the 2021 Rare Cancers, Rare Diseases and Unmet Need (RCRDUN) funding prospect.

COVID-19 Impact Analysis

The COVID-19 analysis includes Pre-COVID Scenario, COVID Scenario, and Post-COVID Scenario along with pricing dynamics (including pricing change during and post-pandemic comparing it to pre-COVID scenarios), demand-supply spectrum (shift in demand and supply owing to trading restrictions, lockdown, and subsequent issues), government initiatives (initiatives to revive market, sector or industry by government bodies) and manufacturers strategic initiatives (what manufacturers did to mitigate the COVID issues will be covered here).

Russia-Ukraine Conflict Analysis

The Russian Federation's invasion of Ukraine on February 24, 2022, generated a huge dislocation of the residents with an assessed 12 million individuals escaping their residences and scouring for protection. Over seven million individuals were internally replaced to additional regions of Ukraine, while five million fled to bordering nations. This has disturbed the market growth in this region thereby negatively impacting the global market growth.

Global Recession Impact Analysis

The healthcare industry is not completely immune to recession, as healthcare institutions thought firings and employment during past financial downturns. That stated, the industry does cope finer than other sectors because of its essential nature. However, the danger of recession threatens the market as inflation persists increasing. The elevated extent of tension about the persistent recession.

Artificial Intelligence Impact Analysis

The employment of artificial intelligence and machine learning in cancer diagnosis, drug development, and precision medicine in oncology to improve the treatment standard and patient experiences are positively impacting the global neuroendocrine tumor treatment market in the forecast period.

Segment Analysis

The global neuroendocrine tumor treatment market is segmented based on therapy type, indication, route of administration, end-user, and region.

The Pancreatic Neuroendocrine Tumor segment is Estimated to Hold a 20% Share of the Global Market by 2030.

Owing to the increasing research in the pancreatic neuroendocrine tumor, the segment is estimated to hold around 20% of the total neuroendocrine tumor treatment market by 2030. For instance, according to a news article published by Northwestern University, a blend therapy practice employing two chemotherapy medications enhanced therapy reaction and progression-free survival in individuals with advanced pancreatic neuroendocrine tumors.

Geographical Analysis

Europe is Estimated to Hold the Second-largest Global Neuroendocrine Tumor Treatment Market Share During the Forecast Period.

Europe is estimated to hold around 28.7% of the total neuroendocrine tumor treatment market owing to the market developments in this region. For instance, in April 2021, Germany's ITM, or Isotopen Technologien Munchen a privately held biotechnology and radiopharmaceutical group of corporations, secured a $109 million round of loan financing to advance its precision oncology pipeline and fund late-stage development for its neuroendocrine cancer program.

Competitive Landscape

The major global players in the market include: Pfizer, Inc., Ipsen Pharmaceuticals, Novartis, AVEO Pharmaceuticals, Inc., Eli Lilly & Company, CK Hutchison Holdings (HUTCHMED), C.H. Boehringer Sohn Ag & Co. KG (Boehringer Ingelheim International GmbH), Lantheus Holdings, Inc., Merck & Co., Inc. and Sanofi among others.

Why Purchase the Report?

  • To visualize the global neuroendocrine tumor treatment market segmentation based on therapy type, indication, route of administration, end-user, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of neuroendocrine tumor treatment market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global neuroendocrine tumor treatment market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Therapy Type
  • 3.2. Snippet by Indication
  • 3.3. Snippet by Route of Administration
  • 3.4. Snippet by End User

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising Cases of Neuroendocrine Tumors.
      • 4.1.1.2. Product Approvals.
      • 4.1.1.3. Increase in Research Activities.
    • 4.1.2. Restraints
      • 4.1.2.1. Treatment Side Effects.
    • 4.1.3. Opportunity
    • 4.1.4. Government Initiatives
    • 4.1.5. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Regulatory Analysis
  • 5.3. Pricing Analysis
  • 5.4. Patent Analysis
  • 5.5. PEST Analysis
  • 5.6. Pipeline Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Before COVID-19 Scenario
    • 6.1.2. Present COVID-19 Scenario
    • 6.1.3. Post COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. Russia-Ukraine Conflict Analysis

8. Global Recession Analysis

9. Artificial Intelligence Impact Analysis

10. By Therapy Type

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 10.1.2. Market Attractiveness Index, By Therapy Type
  • 10.2. Somatostatin analogs (SSAs)
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Targeted therapy
  • 10.4. Others

11. By Indication

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 11.1.2. Market Attractiveness Index, By Indication
  • 11.2. Gastrointestinal*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 11.3. Lungs
  • 11.4. Pancreas
  • 11.5. Others

12. By Route of Administration

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.1.2. Market Attractiveness Index, By Route of Administration
  • 12.2. Oral
    • 12.2.1. Introduction
    • 12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 12.3. Injectable

13. By End User

  • 13.1. Introduction
    • 13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 13.1.2. Market Attractiveness Index, By End User
  • 13.2. Hospitals
    • 13.2.1. Introduction
    • 13.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 13.3. Cancer Research Center
  • 13.4. Ambulatory Surgery Centers

14. By Region

  • 14.1. Introduction
    • 14.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 14.1.2. Market Attractiveness Index, By Region
  • 14.2. North America
    • 14.2.1. Introduction
    • 14.2.2. Key Region-Specific Dynamics
    • 14.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 14.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 14.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 14.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 14.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 14.2.7.1. The U.S.
      • 14.2.7.2. Canada
      • 14.2.7.3. Mexico
  • 14.3. Europe
    • 14.3.1. Introduction
    • 14.3.2. Key Region-Specific Dynamics
    • 14.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 14.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 14.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 14.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 14.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 14.3.7.1. Germany
      • 14.3.7.2. The U.K.
      • 14.3.7.3. France
      • 14.3.7.4. Italy
      • 14.3.7.5. Spain
      • 14.3.7.6. Rest of Europe
  • 14.4. South America
    • 14.4.1. Introduction
    • 14.4.2. Key Region-Specific Dynamics
    • 14.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 14.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 14.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 14.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 14.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 14.4.7.1. Brazil
      • 14.4.7.2. Argentina
      • 14.4.7.3. Rest of South America
  • 14.5. Asia-Pacific
    • 14.5.1. Introduction
    • 14.5.2. Key Region-Specific Dynamics
    • 14.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 14.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 14.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 14.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 14.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 14.5.7.1. China
      • 14.5.7.2. India
      • 14.5.7.3. Japan
      • 14.5.7.4. Australia
      • 14.5.7.5. Rest of Asia-Pacific
  • 14.6. Middle East and Africa
    • 14.6.1. Introduction
    • 14.6.2. Key Region-Specific Dynamics
    • 14.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 14.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 14.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 14.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

15. Competitive Landscape

  • 15.1. Competitive Scenario
  • 15.2. Market Share Analysis
  • 15.3. Mergers and Acquisitions Analysis

16. Company Profiles

  • 16.1. Pfizer, Inc.
    • 16.1.1. Company Overview
    • 16.1.2. Therapy Type Portfolio and Description
    • 16.1.3. Financial Overview
    • 16.1.4. Key Developments
  • 16.2. Ipsen Pharmaceuticals
  • 16.3. Novartis
  • 16.4. AVEO Pharmaceuticals, Inc.
  • 16.5. Eli Lilly & Company
  • 16.6. CK Hutchison Holdings (HUTCHMED)
  • 16.7. C.H. Boehringer Sohn Ag & Co. KG (Boehringer Ingelheim International GmbH)
  • 16.8. Lantheus Holdings, Inc.
  • 16.9. Merck & Co., Inc.
  • 16.10. Sanofi

LIST NOT EXHAUSTIVE

17. Appendix

  • 17.1. About Us and Services
  • 17.2. Contact Us